Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06868212 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
A Phase 3 study of Chronic Spontaneous Urticaria (CSU), sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT06868212: Recruiting Phase 3 study of Chronic Spontaneous Urticaria (CSU), sponsored by Novartis Pharmaceuticals.
NCT06868212 is a Phase 3 study of Chronic Spontaneous Urticaria (CSU) that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 400 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06868212, a Phase 3 study of Chronic Spontaneous Urticaria (CSU), is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily \[b.i.d.\] by mouth \[p.o.\]) compared to dupilumab (600 mg loading dose administered subcutaneously (s.c.) followed by 300 mg every 2 weeks s.c.) at early timepoints (4 weeks and earlier), when administered as an add-on treatment to second generation H1-antihistamines (sgH1-AH) (standard label dose as background therapy) in adult US participants with moderate to severe chronic spontaneous urticaria (CSU) inadequately controlled by sgH1-AHs.
Primary Outcome
The UAS7 is the sum of the Weekly Hives Severity (HSS7) score and the Weekly Itch Severity (ISS7) score, and ranges from 0-42. Weekly scores (HSS7 and ISS7 scores) will be derived by adding up the average daily scores of the 7 days preceding the visit.
Conditions Studied
Interventions
- DRUG Dupilumab
- DRUG Remibrutinib
- DRUG Remibrutinib matching placebo
- DRUG Placebo solution for injection
Study Locations (20)
California
- First OC Dermatology - Fountain Valley
- Ctr for Dermatology Clinical Res - Fremont
- Allergy and Asthma Specialists Group - Huntington Beach
- Orso Health - Long Beach
- Ark Clinical Research - Long Beach
- California Allergy and Asthma Medical Group - Los Angeles
- Dermatology Research Associates - Los Angeles
- One Of A Kind Clinical Research - Napa
- Empire Clinical Research - Pomona
- Allergy and Asthma Consultants - Redwood City
- Norcal Clinical Research - Rocklin
- Integrative Skin Science and Res - Sacramento
Arizona
- Research Solutions of Arizona - Litchfield Park
- Peak Dermatology - Payson
- Premier Allergy Asthma And Immunology - Phoenix
- Avacare Center for Dermatology - Phoenix
- Orso Health - Scottsdale
Alabama
- Allervie Clinical Research - Birmingham
- Cahaba Derm and skin hlth ctr 27 - Birmingham
Arkansas
- Acuro Research Inc - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-07-11 |
| Est. Completion | 2027-05-17 |
| Phase | Phase 3 |
What NCT06868212 shows while recruiting
NCT06868212 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Chronic Spontaneous Urticaria (CSU) appearing as the primary indexed condition, and to 4 interventions - of which Dupilumab is the first listed.
NCT06868212 names 20 study sites across 4 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT06868212 about?
NCT06868212 is a clinical study titled "A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines". This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily \[b.i.d.\] by mouth \[p.o.\]) compared to dupilumab (600 mg loading dose administered subcutaneously (s.c.) followed by 300 mg every 2 weeks s.c.) at early timep...
What is the current status of trial NCT06868212?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2025-07-11. Estimated completion is 2027-05-17.
What conditions does trial NCT06868212 study?
This clinical trial studies the following conditions: Chronic Spontaneous Urticaria (CSU).
What interventions are being tested in trial NCT06868212?
The interventions under investigation include: Dupilumab (DRUG), Remibrutinib (DRUG), Remibrutinib matching placebo (DRUG), Placebo solution for injection (DRUG).
Who is sponsoring clinical trial NCT06868212?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06868212 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06868212's enrollment target sits among peer trials
400 923rd of 2000 higher than 1,039 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI